Cargando…
Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is amongst the deadliest of human cancers, with a median survival rate of just over one year following diagnosis. Characterized by rapid proliferation and diffuse infiltration into the brain, GBM is notoriously difficult to treat, with tumor cells showing limited respon...
Autores principales: | Tilak, Manali, Holborn, Jennifer, New, Laura A., Lalonde, Jasmin, Jones, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918566/ https://www.ncbi.nlm.nih.gov/pubmed/33673213 http://dx.doi.org/10.3390/ijms22041831 |
Ejemplares similares
-
Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
por: Brar, Harpinder K., et al.
Publicado: (2022) -
Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
por: Qin, Anna, et al.
Publicado: (2021) -
A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015) -
Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma
por: Carrasco-García, Estefanía, et al.
Publicado: (2014) -
Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches
por: Alexandru, Oana, et al.
Publicado: (2020)